Overview

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone [r-FSH] starting doses for individualized treatment' (CONSORT) calculator versus given a standard GONAL f® dose of 150 International Unit (IU) per day.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Follicle Stimulating Hormone